Peer-reviewed cryoablation study and Japan expansion news drive ICCM

 

Peer-reviewed cryoablation study and Japan expansion news drive ICCM 30% surge

• June 23 PR highlighted International Journal of Surgery article (top-3 ranked) validating ProSense advantages over RFA for early-stage breast cancer.
• Article reports 99.02% recurrence-free rate in >600 patients (up to 17-year follow-up); comparable outcomes to breast-conserving surgery for tumors ≤2cm.
• Cryoablation enables local anesthesia and visible adjustable ice ball; RFA requires general anesthesia and offers poorer control.
• IceCure preparing to present at Japanese Breast Cancer Society meeting in Kyoto, June 25-27, 2026.
• Distributor Terumo plans PMDA regulatory submission for breast cancer indication in Japan in second half of 2026.
• Builds on prior 70% U.S. ProSense install-base growth post-FDA clearance and $5.5M institutional placement that sparked 200% rally.
• Small-cap volatility amplified move with trading halts; retail/X chatter cited Japan catalyst and short squeeze dynamics.
• Explanation based on company PR, Yahoo Finance data, and market reports; no other discrete catalyst identified for exact June 24 session.

https://finviz.com/stock?t=ICCM&p=d